Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line

por Weiner, F., Schille, J. T., Koczan, D., Wu, X.-F., Beller, M., Junghanss, C., Hewicker-Trautwein, M., Murua Escobar, H., Nolte, I.
Publicado 2021